When you put the guaranteed revenue product on hold which is HIV for 2 trials for Covid, Cd10 and Cd12 that failed to hit primary endpoints , one must question the decision making. That and the CEO deciding to go it alone instead of finding a partner early in the game to carry some of the funding also appears to be a mistake. He now has Dr Kelly looking for partners to share the cost of trials which is good but could be too little too late. Funding issues for the company should be the biggest concern now since time has been wasted in an attempt to go it alone where other small Biotechs with experienced management have decided to partner up with a larger pharma , mainly to fund trials with the right number of patients which is always a challenge for small Biotechs.